Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Bronchoalveolar Lavage in Suspected Interstitial Lung Disease

  Bronchoalveolar lavage remains a frequently discussed investigation when clinicians encounter a patient with suspected interstitial lung disease. It is rarely the first test ordered, but it sits in the diagnostic toolkit alongside high-resolution computed tomography, pulmonary function testing, and serology. In Australian practice, respiratory physicians typically balance the desire for a confident tissue diagnosis against the practical constraints of patient access, Medicare reimbursement, and procedural risk.

  The procedure samples cells and fluid from the distal airways, providing a window into the alveolar environment. For many decades it was seen as a cornerstone of ILD work-up, but its role has narrowed as imaging and serologic testing have improved. Contemporary clinical guidelines now position BAL as a targeted investigation rather than a routine screen, particularly when the HRCT pattern is indeterminate or when alternative diagnoses such as infection or malignancy need to be excluded. Where a confident usual interstitial pneumonia pattern is present on imaging and the clinical context is clear, lavage is often unnecessary.

  The decision to proceed is rarely straightforward and depends on the pretest probability of finding something actionable. In Australia, where multidisciplinary team meetings are embedded in tertiary practice at centres such as Royal Prince Alfred in Sydney or The Alfred in Melbourne, BAL findings are typically interpreted alongside radiology, histopathology, and rheumatology input.

  Diagnostic Context and Differential Considerations

  Bronchoalveolar lavage is most useful when the differential diagnosis is broad and the HRCT does not resolve the question. In these situations the procedure can clarify whether alveolar inflammation, eosinophilia, or infection is driving the clinical picture. Cellular profiles that favour hypersensitivity pneumonitis, sarcoidosis, or drug-induced lung disease can shift management without the need for surgical lung biopsy.

  Australian clinicians working in regional and remote areas face particular challenges when arranging BAL. Patients from far western New South Wales or the Pilbara may need to be transferred to a tertiary centre, which influences the threshold for invasive testing. Many respiratory physicians will reserve lavage for situations where the result will clearly change management, recognising the logistical burden on patients who travel hundreds of kilometres for the procedure.

  Technical Approach and Sampling Protocols

  The technique involves wedging a bronchoscope into a segmental bronchus and instilling aliquots of saline, which are then aspirated and sent for cytologic, microbiologic, and sometimes flow cytometric analysis. Recovery volume, the site of sampling, and the clinical context all influence interpretation. Lavage from the most affected segment on HRCT, often a lower lobe or the right middle lobe, is generally preferred.

  In Australia, the procedure is performed by respiratory physicians with procedural credentials, usually in a public hospital bronchoscopy suite or in a private day-procedure facility funded through Medicare. Recovery and processing are handled locally, although some sites send samples to reference laboratories in capital cities. Standard precautions include checking the patient's coagulopathy status, reviewing antiplatelet and anticoagulant therapy, and ensuring that appropriate microbial transport media are available for atypical organisms.

  Interpreting Cytology and Microbiology

  The differential cell count provides the most informative component of BAL analysis. A lymphocytic predominance raises the possibility of hypersensitivity pneumonitis, sarcoidosis, or cellular nonspecific interstitial pneumonia, while an eosinophilic pattern prompts consideration of eosinophilic pneumonia or drug reaction. Neutrophilic predominance is less specific but can reflect infection, aspiration, or end-stage fibrosis.

  Microbiology is equally important. Malignancy is not directly diagnosed by BAL in most cases, though cytologic examination occasionally identifies malignant cells. Bacterial, fungal, and mycobacterial cultures help exclude opportunistic infection, particularly in patients on immunosuppression or those with atypical presentations. Pneumocystis and Nocardia should remain on the radar in immunocompromised hosts, and atypical mycobacteria are a genuine consideration in older Australians with structural lung disease.

  BAL in Connective Tissue Disease-Associated ILD

  Lavage has a particularly nuanced role when interstitial lung disease is suspected in the setting of rheumatoid arthritis, systemic sclerosis, or other connective tissue diseases. Because these patients may be candidates for immunosuppressive therapy, confirming the absence of infection before escalation is critical. Recent work highlighted in rheumatoid arthritis ILD research emphasises how BAL can support safer treatment decisions in this population.

  Rheumatology and respiratory teams in Australia commonly discuss BAL findings in joint multidisciplinary meetings, particularly at large academic centres. The procedure helps clinicians distinguish between active inflammation that may respond to immunomodulation and progressive fibrotic disease that may require antifibrotic therapy. The decision is rarely binary, and the result is usually interpreted alongside serology, imaging, and the trajectory of symptoms.

  Limitations and Safety Considerations

  Bronchoalveolar lavage is not without risk. Fever, transient hypoxia, and a small risk of bleeding or pneumothorax are well recognised. In patients with advanced fibrosis or limited respiratory reserve, the procedure may be poorly tolerated, and the diagnostic yield is often lower because of structural distortion and impaired recovery.

  The procedure also has a real but limited sensitivity for diffuse disease. Focal processes can be missed, and a "normal" lavage does not exclude evolving fibrosis. Australian guidelines, including those issued by the Thoracic Society of Australia and New Zealand, emphasise that BAL should never replace sound clinical reasoning or substitute for surgical lung biopsy when a confident diagnosis is essential and cannot be obtained otherwise.

  Practical Recommendations for the Respiratory Clinician

  • Reserve BAL for cases where the HRCT pattern is indeterminate or where infection must be excluded before immunosuppression.
  • Sample the most affected segment on imaging and document the volume instilled and recovered.
  • Send fluid for differential cell count, microbiology including mycobacteria and fungi, and cytology in selected cases.
  • Discuss findings in a multidisciplinary meeting involving respiratory, radiology, rheumatology, and pathology input where available.
  • Weigh procedural risk against anticipated yield, particularly in patients with advanced fibrosis or significant comorbidity.
  • Recognise that a normal lavage does not exclude ILD and should not delay further investigation when clinical suspicion remains high.
  • Document the indication, consent process, and any sedation used in line with local hospital policy and Medicare requirements.

  When BAL is performed for the right reasons, in the right patient, and interpreted by a team that understands its limitations, it adds genuine value to the diagnostic pathway. For clinicians refining their approach to suspected interstitial lung disease, the next practical step is to review the local multidisciplinary referral pathway and confirm which cases from your own service should be flagged for bronchoscopic sampling at the next team meeting.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)